Maria Ricci Memorial Lectureship in Medical Oncology

Queen's University ITS will be performing network maintenance on Saturday, August 19 beginning at 12 am and lasting until approximately 5 am EDT. 

Access to services that are physically housed on campus, such EDC, Mango and the main Canadian Cancer Trials Group website will NOT be available from off campus through the maintenance period.

Maria Ricci Memorial Lectureship in Medical Oncology

    Maria was GlaxoSmithKline's Scientific Development Manager in oncology when her life ended tragically in January 2007 while traveling on GSK-related business. She was committed to making a difference for Canadian patients. Maria was instrumental in bridging relationships between global GSK and the Canadian medical community and facilitated Canadian scientific and medical engagement in the development of GSK's oncology pipeline.


    Maria was well respected by her colleagues and peers and remembered for her enthusiasm and passionate approach to work and life. She was a PhD candidate in Microbiology & Immunology at McGill University and received her MSc in pharmacology and toxicology from the University of Western Ontario.


    The Maria Ricci Memorial Lectureship in Medical Oncology was established in 2007 with funding provided by GlaxoSmithKline Inc. in memory of Maria Ricci. The proceeds of this endowment will be used to support this lectureship at the Canadian Cancer Trials Group in the area of medical oncology.

     

    Year Lecturer Title
    2013 Dr. Frances Shepherd A Journey from Nihilism to Hope Through Bench to Bedside Research in Non-Small Cell Lung Cancer
    2012 Dr. Mark Levine Research to Clinical Practice: The Freedom of Innovation versus the Tyranny of Evidence
    2011 Dr. Joseph M Connors What We Are Learning about Lymphoma Using Genomic Techniques
    2010 Dr. Kathleen Pritchard The Oxford Overview – Is it still relevant in 2010?
    2009 Dr. Pamela Goodwin Insulin and Breast Cancer – A Potential Therapeutic Target?
    2008 Dr. Karen Gelmon The Hit and Miss of Targeted Therapy for Breast Cancer